| Tess E Shymanski, OTR/L | |
|
3851 Commercial Center Dr, Ladson, SC 29456-4146 | |
| (843) 314-5434 | |
| (888) 510-9156 |
| Full Name | Tess E Shymanski |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3851 Commercial Center Dr, Ladson, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396485397 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 6477 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tess E Shymanski, OTR/L 3851 Commercial Center Dr, Ladson, SC 29456-4146 Ph: (843) 314-5434 | Tess E Shymanski, OTR/L 3851 Commercial Center Dr, Ladson, SC 29456-4146 Ph: (843) 314-5434 |
News Archive
A new gene that influences susceptibility to late-onset Alzheimer's disease (LOAD) has been identified by an international research team that analyzed the genomes of more than a thousand people with and without the disorder.
The common perception that if medication is natural then it must be safe has recently come under fire from a researh by a Consumer Reports magazine. The consumer publication found a dozen herbal supplements, some banned in Asia, Europe and Canada but widely available in the United States, may cause cancer, kidney or liver damage and even death.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
There is a significant association between recurrent group A streptococcal tonsillopharyngitis and vitamin D deficiency, say Israeli researchers who call for research into whether supplementation could prevent the condition.
› Verified 6 days ago
Kathryn Mazingo, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3851 Commercial Center Dr, Ladson, SC 29456 Phone: 843-314-5434 | |
Jana Kitch, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9565 Hwy 78, Bldg 700 Ste 102, Ladson, SC 29456 Phone: 843-314-5434 | |
Kieran E Carson, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3851 Commercial Center Dr, Ladson, SC 29456 Phone: 843-314-5434 | |
Erin Delaney Hood, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9565 Highway 78 Ste 102, Ladson, SC 29456 Phone: 843-569-4546 Fax: 843-569-4535 | |
Kathryn Griffin, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3851 Commercial Center Dr, Ladson, SC 29456 Phone: 843-314-5434 | |
Adair Turturro, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3851 Commercial Center Dr, Ladson, SC 29456 Phone: 843-314-5434 Fax: 843-277-6237 | |
Emily Patten, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3851 Commercial Center Dr, Ladson, SC 29456 Phone: 843-314-5434 |